Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has issued an announcement.
Lepu Biopharma Co., Ltd. has announced that it received a filing notice from the China Securities Regulatory Commission (CSRC) regarding its application for the full circulation of H shares. This development involves converting 54,268,364 unlisted domestic shares into H shares for listing on the Hong Kong Stock Exchange. While the CSRC filing has been completed, the company must still fulfill additional procedures required by relevant regulatory authorities. The announcement indicates potential changes in the company’s share structure and market presence, advising shareholders and investors to exercise caution.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on developing and commercializing innovative pharmaceutical products, with a market focus on H shares listed on the Stock Exchange of Hong Kong.
Average Trading Volume: 19,004,571
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.66B
For an in-depth examination of 2157 stock, go to TipRanks’ Stock Analysis page.